In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens
Date
2009
Authors
Jones, R.
Bell, J.
Sader, H.
Turnidge, J.
Stilwell, M.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Diagnostic Microbiology and Infectious Disease, 2009; 63(4):434-439
Statement of Responsibility
Ronald N. Jones, Jan M. Bell, Helio S. Sader, John D. Turnidge, and Matthew G. Stilwell
Conference Name
Abstract
Doripenem, a new 1beta-methyl parenteral carbapenem, has very broad-spectrum activity against Gram-positive and Gram-negative aerobic bacteria. As noted here, the spectrum and potency extended to many rarely isolated species sampled by the Doripenem Global Surveillance Program. Among the species or species groups with <or=0.14% prevalence (1959 strains tested), doripenem was active against 98.9% of Enterobacteriaceae at <or=0.5 microg/mL. Similarly, more than 90% of other rarely isolated Gram-negative species isolates (Aeromonas spp., Delftia acidovorans, Haemophilus parainfluenzae, Neisseria meningitidis, Ochrobactrum anthropi, Pasteurella multocida, Pseudomonas oryzihabitans, and Pseudomonas stutzeri) were inhibited by <or=2 microg/mL of doripenem. The low-prevalence Gram-positive pathogens were generally less doripenem susceptible with MIC(90) results at >0.25 microg/mL for all tested species except Lactococcus garvieae, Listeria monocytogenes, and Micrococcus spp. In conclusion, doripenem exhibited a very wide spectrum but variable potencies against uncommonly cultured aerobic bacterial pathogens isolated in 2003 to 2007. These results confirm the potential use of this new carbapenem for broad-spectrum empiric or directed antimicrobial therapy.
School/Discipline
Dissertation Note
Provenance
Description
Copyright © 2009 Elsevier Inc. All rights reserved.